Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma

Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-07, Vol.15 (7), p.e0236159-e0236159
Main Authors: Gunerka, Paweł, Gala, Kamila, Banach, Martyna, Dominowski, Jakub, Hucz-Kalitowska, Joanna, Mulewski, Krzysztof, Hajnal, Agnes, Mikus, Endre G., Smuga, Damian, Zagozda, Marcin, Dubiel, Krzysztof, Pieczykolan, Jerzy, Zygmunt, Beata M., Wieczorek, Maciej
Format: Article
Language:English
Subjects:
Allergens
Allergies
Antigens
Asthma
Biology and Life Sciences
Cytokines
Drugs
Inflammatory diseases
Inhalation
Inhibitors
Lung diseases
Lungs
Medicine and Health Sciences
R&D
Research & development
Respiration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c503t-f4441a6293ee3b3eaa287bb2ab810880995fefd18ea61049c4fee782a0add4f13
cites cdi_FETCH-LOGICAL-c503t-f4441a6293ee3b3eaa287bb2ab810880995fefd18ea61049c4fee782a0add4f13
container_end_page e0236159
container_issue 7
container_start_page e0236159
container_title PloS one
container_volume 15
creator Gunerka, Paweł
Gala, Kamila
Banach, Martyna
Dominowski, Jakub
Hucz-Kalitowska, Joanna
Mulewski, Krzysztof
Hajnal, Agnes
Mikus, Endre G.
Smuga, Damian
Zagozda, Marcin
Dubiel, Krzysztof
Pieczykolan, Jerzy
Zygmunt, Beata M.
Wieczorek, Maciej
description Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo.
doi_str_mv 10.1371/journal.pone.0236159
format article
fullrecord <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_2426532051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b8f73c74126948ec925662c8c74b036c</doaj_id><sourcerecordid>2426532051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-f4441a6293ee3b3eaa287bb2ab810880995fefd18ea61049c4fee782a0add4f13</originalsourceid><addsrcrecordid>eNptkkuOEzEQhlsIxAwDN0DCEptZkOBX290bpFHEI2IksoC1Ve2unjhy2sF2Ig3X4CqcgzPhTBrEIFYuV33110NVVc8ZnTOh2etN2McR_HwXRpxTLhSr2wfVOWsFnylOxcO_7LPqSUobSmvRKPW4OhNcU15-59X3VUTr3egseGLXEMFmjO4bZBdGEgayWF0Lyme8Fq8IkIQebXYHJG5cu87lEI_Qaik-_vxRgETyGomFsXc9ZCRDiR89hQYPhb4lOSLkLY6ZFIrsIh6KPRW7Snm9hafVowF8wmfTe1F9eff28-LD7PrT--Xi6npmayrybJBSMlC8FYiiEwjAG911HLqG0aahbVsPOPSsQVCMytbKAVE3HCj0vRyYuKhenHR3PiQz7TMZLrmqRVnPkVieiD7Axuyi20K8NQGcuXOEeGMgZmc9mq4ZtLBaMq5a2aBtea0Ut01xdVQoW7TeTNX23RZ7W6aO4O-J3o-Mbm1uwsFoobXUsghcTgIxfN1jymbrkkXvYcSwv-tbC9pySgv68h_0_9PJE2VjSCni8KcZRs3xxn5nmeONmenGxC88Asbt</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2426532051</pqid></control><display><type>article</type><title>Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma</title><source>Publicly Available Content Database</source><source>PubMed</source><creator>Gunerka, Paweł ; Gala, Kamila ; Banach, Martyna ; Dominowski, Jakub ; Hucz-Kalitowska, Joanna ; Mulewski, Krzysztof ; Hajnal, Agnes ; Mikus, Endre G. ; Smuga, Damian ; Zagozda, Marcin ; Dubiel, Krzysztof ; Pieczykolan, Jerzy ; Zygmunt, Beata M. ; Wieczorek, Maciej</creator><contributor>Rishi, Arun</contributor><creatorcontrib>Gunerka, Paweł ; Gala, Kamila ; Banach, Martyna ; Dominowski, Jakub ; Hucz-Kalitowska, Joanna ; Mulewski, Krzysztof ; Hajnal, Agnes ; Mikus, Endre G. ; Smuga, Damian ; Zagozda, Marcin ; Dubiel, Krzysztof ; Pieczykolan, Jerzy ; Zygmunt, Beata M. ; Wieczorek, Maciej ; Rishi, Arun</creatorcontrib><description>Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0236159</identifier><identifier>PMID: 32702053</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Allergens ; Allergies ; Antigens ; Asthma ; Biology and Life Sciences ; Cytokines ; Drugs ; Inflammatory diseases ; Inhalation ; Inhibitors ; Lung diseases ; Lungs ; Medicine and Health Sciences ; R&amp;D ; Research &amp; development ; Respiration</subject><ispartof>PloS one, 2020-07, Vol.15 (7), p.e0236159-e0236159</ispartof><rights>2020 Gunerka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Gunerka et al 2020 Gunerka et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-f4441a6293ee3b3eaa287bb2ab810880995fefd18ea61049c4fee782a0add4f13</citedby><cites>FETCH-LOGICAL-c503t-f4441a6293ee3b3eaa287bb2ab810880995fefd18ea61049c4fee782a0add4f13</cites><orcidid>0000-0002-1680-7226</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2426532051/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2426532051?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids></links><search><contributor>Rishi, Arun</contributor><creatorcontrib>Gunerka, Paweł</creatorcontrib><creatorcontrib>Gala, Kamila</creatorcontrib><creatorcontrib>Banach, Martyna</creatorcontrib><creatorcontrib>Dominowski, Jakub</creatorcontrib><creatorcontrib>Hucz-Kalitowska, Joanna</creatorcontrib><creatorcontrib>Mulewski, Krzysztof</creatorcontrib><creatorcontrib>Hajnal, Agnes</creatorcontrib><creatorcontrib>Mikus, Endre G.</creatorcontrib><creatorcontrib>Smuga, Damian</creatorcontrib><creatorcontrib>Zagozda, Marcin</creatorcontrib><creatorcontrib>Dubiel, Krzysztof</creatorcontrib><creatorcontrib>Pieczykolan, Jerzy</creatorcontrib><creatorcontrib>Zygmunt, Beata M.</creatorcontrib><creatorcontrib>Wieczorek, Maciej</creatorcontrib><title>Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma</title><title>PloS one</title><description>Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo.</description><subject>Allergens</subject><subject>Allergies</subject><subject>Antigens</subject><subject>Asthma</subject><subject>Biology and Life Sciences</subject><subject>Cytokines</subject><subject>Drugs</subject><subject>Inflammatory diseases</subject><subject>Inhalation</subject><subject>Inhibitors</subject><subject>Lung diseases</subject><subject>Lungs</subject><subject>Medicine and Health Sciences</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Respiration</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkkuOEzEQhlsIxAwDN0DCEptZkOBX290bpFHEI2IksoC1Ve2unjhy2sF2Ig3X4CqcgzPhTBrEIFYuV33110NVVc8ZnTOh2etN2McR_HwXRpxTLhSr2wfVOWsFnylOxcO_7LPqSUobSmvRKPW4OhNcU15-59X3VUTr3egseGLXEMFmjO4bZBdGEgayWF0Lyme8Fq8IkIQebXYHJG5cu87lEI_Qaik-_vxRgETyGomFsXc9ZCRDiR89hQYPhb4lOSLkLY6ZFIrsIh6KPRW7Snm9hafVowF8wmfTe1F9eff28-LD7PrT--Xi6npmayrybJBSMlC8FYiiEwjAG911HLqG0aahbVsPOPSsQVCMytbKAVE3HCj0vRyYuKhenHR3PiQz7TMZLrmqRVnPkVieiD7Axuyi20K8NQGcuXOEeGMgZmc9mq4ZtLBaMq5a2aBtea0Ut01xdVQoW7TeTNX23RZ7W6aO4O-J3o-Mbm1uwsFoobXUsghcTgIxfN1jymbrkkXvYcSwv-tbC9pySgv68h_0_9PJE2VjSCni8KcZRs3xxn5nmeONmenGxC88Asbt</recordid><startdate>20200723</startdate><enddate>20200723</enddate><creator>Gunerka, Paweł</creator><creator>Gala, Kamila</creator><creator>Banach, Martyna</creator><creator>Dominowski, Jakub</creator><creator>Hucz-Kalitowska, Joanna</creator><creator>Mulewski, Krzysztof</creator><creator>Hajnal, Agnes</creator><creator>Mikus, Endre G.</creator><creator>Smuga, Damian</creator><creator>Zagozda, Marcin</creator><creator>Dubiel, Krzysztof</creator><creator>Pieczykolan, Jerzy</creator><creator>Zygmunt, Beata M.</creator><creator>Wieczorek, Maciej</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1680-7226</orcidid></search><sort><creationdate>20200723</creationdate><title>Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma</title><author>Gunerka, Paweł ; Gala, Kamila ; Banach, Martyna ; Dominowski, Jakub ; Hucz-Kalitowska, Joanna ; Mulewski, Krzysztof ; Hajnal, Agnes ; Mikus, Endre G. ; Smuga, Damian ; Zagozda, Marcin ; Dubiel, Krzysztof ; Pieczykolan, Jerzy ; Zygmunt, Beata M. ; Wieczorek, Maciej</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-f4441a6293ee3b3eaa287bb2ab810880995fefd18ea61049c4fee782a0add4f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Allergens</topic><topic>Allergies</topic><topic>Antigens</topic><topic>Asthma</topic><topic>Biology and Life Sciences</topic><topic>Cytokines</topic><topic>Drugs</topic><topic>Inflammatory diseases</topic><topic>Inhalation</topic><topic>Inhibitors</topic><topic>Lung diseases</topic><topic>Lungs</topic><topic>Medicine and Health Sciences</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Respiration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gunerka, Paweł</creatorcontrib><creatorcontrib>Gala, Kamila</creatorcontrib><creatorcontrib>Banach, Martyna</creatorcontrib><creatorcontrib>Dominowski, Jakub</creatorcontrib><creatorcontrib>Hucz-Kalitowska, Joanna</creatorcontrib><creatorcontrib>Mulewski, Krzysztof</creatorcontrib><creatorcontrib>Hajnal, Agnes</creatorcontrib><creatorcontrib>Mikus, Endre G.</creatorcontrib><creatorcontrib>Smuga, Damian</creatorcontrib><creatorcontrib>Zagozda, Marcin</creatorcontrib><creatorcontrib>Dubiel, Krzysztof</creatorcontrib><creatorcontrib>Pieczykolan, Jerzy</creatorcontrib><creatorcontrib>Zygmunt, Beata M.</creatorcontrib><creatorcontrib>Wieczorek, Maciej</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gunerka, Paweł</au><au>Gala, Kamila</au><au>Banach, Martyna</au><au>Dominowski, Jakub</au><au>Hucz-Kalitowska, Joanna</au><au>Mulewski, Krzysztof</au><au>Hajnal, Agnes</au><au>Mikus, Endre G.</au><au>Smuga, Damian</au><au>Zagozda, Marcin</au><au>Dubiel, Krzysztof</au><au>Pieczykolan, Jerzy</au><au>Zygmunt, Beata M.</au><au>Wieczorek, Maciej</au><au>Rishi, Arun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma</atitle><jtitle>PloS one</jtitle><date>2020-07-23</date><risdate>2020</risdate><volume>15</volume><issue>7</issue><spage>e0236159</spage><epage>e0236159</epage><pages>e0236159-e0236159</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Asthma is a common chronic inflammatory disease. Although effective asthma therapies are available, part of asthmatic population do not respond to these treatment options. In this work we present the result of development of CPL302-253 molecule, a selective PI3Kδ inhibitor. This molecule is intended to be a preclinical candidate for dry powder inhalation in asthma treatment. Studies we performed showed that this molecule is safe and effective PI3Kδ inhibitor that can impact many immune functions. We developed a short, 15-day HDM induced asthma mouse model, in which we showed that CPL302-253 is able to block inflammatory processes leading to asthma development in vivo.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>32702053</pmid><doi>10.1371/journal.pone.0236159</doi><orcidid>https://orcid.org/0000-0002-1680-7226</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2020-07, Vol.15 (7), p.e0236159-e0236159
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2426532051
source Publicly Available Content Database; PubMed
subjects Allergens
Allergies
Antigens
Asthma
Biology and Life Sciences
Cytokines
Drugs
Inflammatory diseases
Inhalation
Inhibitors
Lung diseases
Lungs
Medicine and Health Sciences
R&D
Research & development
Respiration
title Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A20%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preclinical%20characterization%20of%20CPL302-253,%20a%20selective%20inhibitor%20of%20PI3K%CE%B4,%20as%20the%20candidate%20for%20the%20inhalatory%20treatment%20and%20prevention%20of%20Asthma&rft.jtitle=PloS%20one&rft.au=Gunerka,%20Pawe%C5%82&rft.date=2020-07-23&rft.volume=15&rft.issue=7&rft.spage=e0236159&rft.epage=e0236159&rft.pages=e0236159-e0236159&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0236159&rft_dat=%3Cproquest_plos_%3E2426532051%3C/proquest_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c503t-f4441a6293ee3b3eaa287bb2ab810880995fefd18ea61049c4fee782a0add4f13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2426532051&rft_id=info:pmid/32702053&rfr_iscdi=true